<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954820</url>
  </required_header>
  <id_info>
    <org_study_id>PROICM 2021-04 REL</org_study_id>
    <nct_id>NCT04954820</nct_id>
  </id_info>
  <brief_title>Assessment of the Schema of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor</brief_title>
  <acronym>ReLUTH</acronym>
  <official_title>A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera® ([177LU]LU-DOTA-TATE) in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, since the reimbursement of Lutathera®, this treatment is allowed for retreatment&#xD;
      if patients still fulfill the criteria of its indication and 4 news cycles could be proposed.&#xD;
      However, clinical practices are heterogeneous regarding the number of new cycles and most&#xD;
      teams perform only two additional cycles (every 8 weeks). Therefore, the coordinator propose&#xD;
      to evaluate the efficacy of two additional cycle of Lutathera® versus active surveillance in&#xD;
      patients already retreated with two cycles Lutathera® for a new progression of intestinal&#xD;
      neuroendocrine tumor and who previously received the 4 cycles of treatment with a clinical&#xD;
      benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NETTER-1 clinical trial compared peptide receptor radionuclide therapy (PRRT) with&#xD;
      [177Lu]Lu-DOTA-TATE (Lutathera®) every eight weeks (4 doses) plus 30 mg octreotide LAR every&#xD;
      4 weeks with high dose (60 mg) of octreotide LAR every 4 weeks in patients with progressive&#xD;
      and unresectable midgut neuroendocrine well differentiated (G1, G2) tumors (NETs) with&#xD;
      somatostatin-receptor positive imaging (SSTRi+). Lutathera® improves both median progression&#xD;
      free survival (PFS) (28.4 months vs 8.5 months) and median overall survival (OS) (&quot;not&#xD;
      reached&quot; vs 27.4 months) with a follow-up of 42 months. Lutathera® also has an impact on&#xD;
      quality of life. Therefore, this treatment was approved by the European Medicines Agency and&#xD;
      is now reimbursed in France in that specific indication. Despite these promising results,&#xD;
      progression will occur in most of patients within a variable time with limited treatment&#xD;
      options left. Retreatment with additional cycles of Lutathera® may be an option. Van der Zwan&#xD;
      et al. showed in a large retrospective cohort (the &quot;ROTTERDAM cohort&quot;) a median PFS of 14.6&#xD;
      months after retreatment with two additional cycles of PRRT with [177Lu]Lu-DOTA-TATE and a&#xD;
      significant longer OS than in the non-randomized control group. Interestingly, the safety was&#xD;
      similar in salvage group than in initial PRRT: no grade (G) 3/4 renal toxicity occurred and&#xD;
      hematological toxicities were similar to the group of patients who received the initial&#xD;
      treatment (4 cycles). In a smaller cohort of 15 patients, Yordanova et al. showed that 8 or&#xD;
      more cycles of [177Lu]Lu-DOTA-TATE were well tolerated and led to a survival improvement. In&#xD;
      this study, each salvage therapy consisted of 2 or 3 cycles. No severe (G3, G4) renal&#xD;
      toxicity or G4 adverse event occurred. In France, since the reimbursement of Lutathera®, this&#xD;
      treatment is allowed for retreatment if patients still fulfill the criteria of its indication&#xD;
      and 4 news cycles could be proposed. However, clinical practices are heterogeneous regarding&#xD;
      the number of new cycles and most teams perform only two additional cycles (every 8 weeks).&#xD;
      Therefore, the coordinator propose to evaluate the efficacy of two additional cycle of&#xD;
      Lutathera® versus active surveillance in patients already retreated with two cycles&#xD;
      Lutathera® for a new progression of intestinal neuroendocrine tumor and who previously&#xD;
      received the 4 cycles of treatment with a clinical benefit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>It's a prospective, national, multicenter, open-label, randomized, phase II study, to compare 2 additional cycles of Lutathera® versus active surveillance in patients who already received two cycles of &quot;Second PRRT&quot; (already retreated with two cycles).&#xD;
Written informed consent will be collected before any study related procedures take place.&#xD;
Patients previously treated with 4 cycles of Lutathera® will be registered after a first progression (clinic, biologic and/or radiologic) of their neuroendocrine tumor.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of two additional cycles of Lutathera® (one injection every two months), compared to active surveillance during 6 months in patients already retreated with two cycles.</measure>
    <time_frame>assessement every cycle (every 8 weeks) 6 months from randomization</time_frame>
    <description>defined as a change of tumoral assessment (Complete Response, Partial Response and Stable Disease from RECIST v1.1) with an evaluation every 2 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of two additional cycles of Lutathera® (one injection every two months), compared to active surveillance in term of Safety</measure>
    <time_frame>during 6 months in patients already retreated with two cycles (each cycle is 8 weeks)</time_frame>
    <description>Number and type of adverse event according to NCI-CTCAE v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of two additional cycles of Lutathera® (one injection every two months), compared to active surveillance in term of Progression free survival</measure>
    <time_frame>the time without progression of disease during 5 years after the treatment,</time_frame>
    <description>the time from randomization until documented disease progression on radiological tumor assessment (as evaluated by an independent central review by radiologists blindly of the treatment assignments according to RECIST v1.1) or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of two additional cycles of Lutathera® (one injection every two months), compared to active surveillance in term of Overall survival</measure>
    <time_frame>the time without death during 5 years after the treatment</time_frame>
    <description>the time from randomization until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess quality of life</measure>
    <time_frame>during and after treatment in both arm : every 8 wweks during the treatment, every 3 months during 1 year post treatment and every year during 4 years post treatment</time_frame>
    <description>Quality of life will be measured by EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer, Quality-of-life questionnaire C30, no min and max values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess quality of life</measure>
    <time_frame>during and after treatment in both arm : every 8 wweks during the treatment, every 3 months during 1 year post treatment and every year during 4 years post treatment</time_frame>
    <description>Quality of life will be measured by EORTC GI.NET21 questionnaire (European Organisation for Research and Treatment of Cancer, gastrointestinal neuroendocrine tumor, no min and max values)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Intestinal Well Differentiated Endocrine Tumor</condition>
  <condition>Progressive Disease</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 additional infusions of Lutathera® according to the marketing authorization schema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment with active monitoring (clinical, biological and radiological follow-up) every 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lutathera</intervention_name>
    <description>2 additional infusions of Lutathera®</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years,&#xD;
&#xD;
          -  Histologically proven intestinal G1 or G2 neuroendocrine tumors (NET),&#xD;
&#xD;
          -  Patient previously treated with 4 cycles of Lutathera® (defined as &quot;First PRRT&quot;),&#xD;
&#xD;
          -  Disease control after &quot;First PRRT&quot; ≥ 12 months,&#xD;
&#xD;
          -  Patient presenting a progression of disease (clinic, biologic and/or radiologic) after&#xD;
             a first PRRT,&#xD;
&#xD;
          -  Decision of retreatment with Lutathera® (defined as &quot;Second PRRT&quot;) validated by&#xD;
             RENATEN and/or multidisciplinary tumor board and in the scope of the French&#xD;
             reimbursement process,&#xD;
&#xD;
          -  ECOG performance status 0-2,&#xD;
&#xD;
          -  Life expectancy ≥ 6 months as prognosticated by the physician,&#xD;
&#xD;
          -  Somatostatin receptor imaging positive imaging (SSTRi+) disease within 4 months prior&#xD;
             to randomization: (may be PET imaging (68Ga-based SSTR analogues) or scintigraphy&#xD;
             imaging: 111In-pentetreotide or 99mTc-octreotide. At least 90% of lesions must be&#xD;
             positive for SSTRi with a significant uptake (&gt;= liver of surrounding tissue),&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1 (Appendix 1), on CT/MRI scans, defined as at least 1&#xD;
             lesion with ≥ 1 cm in longest diameter, and ≥ 2 radiological tumors lesions in total,&#xD;
&#xD;
          -  Adequate bone marrow reserve (Hb &gt; 8 g/dl, neutrophils ≥ 1500/mm³ and platelets ≥ 80&#xD;
             000/mm³),&#xD;
&#xD;
          -  Negative pregnancy test in women of childbearing potential (the β-HCG dosage must be ≤&#xD;
             4 days before inclusion). Women who have no reproductive potential are postmenopausal&#xD;
             women or women who have had permanent sterilization, eg. tubal occlusion,&#xD;
             hysterectomy, bilateral salpingectomy),&#xD;
&#xD;
          -  Effective contraception in men or women of childbearing or pre-menopausal age and up&#xD;
             to a minimum of 6 months following the end of treatment,&#xD;
&#xD;
          -  Patient´s signed written informed consent,&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests and other study procedures,&#xD;
&#xD;
          -  Affiliation to the French Social Security System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who did not respond (no CR, PR or SD) to &quot;first PRRT&quot;.&#xD;
&#xD;
          -  Radiological progression after two cycles of &quot;Second PRRT&quot; according to RECIST version&#xD;
             1.1,&#xD;
&#xD;
          -  Grade 4 hematotoxicity and/or nephrotoxicity during the initial PRRT, or unresolved&#xD;
             AEs categorized as Grade 2 or higher (as per Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE v5.0) from previous PRRT cycles or any other therapy for NET, excluding&#xD;
             alopecia and peripheral neuropathy,&#xD;
&#xD;
          -  Pancreatic NET,&#xD;
&#xD;
          -  NeuroEndocrine Carcinoma,&#xD;
&#xD;
          -  Prior external beam radiation therapy to more than 25% of the bone marrow,&#xD;
&#xD;
          -  Severe renal (measured Glomerular Filtration Rate (GFR) according to Modification of&#xD;
             Diet in Renal Disease (MDRD) &lt; 40 mL/min or nephrotic syndrome) or hepatic&#xD;
             insufficiency (Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) &gt; 2.5&#xD;
             x ULN or ALT/AST &gt; 5 x ULN if liver function abnormalities are due to the underlying&#xD;
             malignancy and/or total serum bilirubin &gt; 2.5 x ULN),&#xD;
&#xD;
          -  Serum albumin &lt; 3.0 g/dL unless prothrombin time is within the normal range,&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus as defined by a fasting blood glucose above 2 ULN,&#xD;
&#xD;
          -  Uncontrolled decompensated heart failure, myocardial infarction uncontrolled, stroke,&#xD;
             pulmonary embolism or revascularization procedure, unstable angina pectoris,&#xD;
             uncontrolled cardiac arrhythmia, and clinically significant bradycardia during the&#xD;
             last 12 months,&#xD;
&#xD;
          -  Hypertension that cannot be controlled despite medications (≥ 160/95 mmHg despite&#xD;
             optimal medical therapy)&#xD;
&#xD;
          -  Brain metastases (unless these metastases have been treated and stabilized for at&#xD;
             least 24 weeks, prior to enrolment in the study. Patients with a history of brain&#xD;
             metastases must have a head CT scan with contrast or MRI to document stable disease&#xD;
             prior to enrolment in the study),&#xD;
&#xD;
          -  Pregnancy or breast feeding,&#xD;
&#xD;
          -  Substance abuse, medical, psychological, or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results,&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs, study drug classes, or any&#xD;
             constituent of the products,&#xD;
&#xD;
          -  Concomitant participation or participation within the last 30 days in another clinical&#xD;
             trial,&#xD;
&#xD;
          -  History of other solid tumor in 5 years before the inclusion excepted of cancer in&#xD;
             situ of the cervix and skin cancer (basal or squamous cell) treated and controlled.&#xD;
&#xD;
          -  Legal incapacity or physical, psychological or mental status interfering with the&#xD;
             patient's ability to sign the informed consent or to terminate the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Pierre BLEUSE, MD</last_name>
    <phone>0467613102</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Phillipe METGES, MD</last_name>
      <email>jean-philippe.metges@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices civils de LYON - GHE</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline MOREAU-TRIBY, MD</last_name>
      <email>caroline.moreau-triby@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anthony KELLY, MD</last_name>
      <email>Antony.KELLY@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes (CHUGA)</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Philippe VUILLEZ, MD</last_name>
      <email>jpvuillez@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amandine BERON, PR</last_name>
      <email>Amandine.beron@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre léon bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne-Laure GIRAUDET, MD</last_name>
      <email>anneLaure.giraudet@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>David TAIEB, PR</last_name>
      <email>david.taieb@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel DESHAYES, MD</last_name>
      <email>emmanuel.deshayes@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine ANSQUER, MD</last_name>
      <email>catherine.ansquer@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Colette ZWARTHOED, MD</last_name>
      <email>colette.zwarthoed@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Charlotte LUSSEY, MD</last_name>
      <email>charlotte.lussey@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florence TENENBAUM, MD</last_name>
      <email>florence.tenenbaum@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ghoufrane TLILI, MD</last_name>
      <email>ghoufrane.tlili@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno MAUCHERAT, MD</last_name>
      <email>bruno.maucherat@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lawrence DIERICKX, MD</last_name>
      <email>dierickx.lawrence@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elodie CHEVALIER, MD</last_name>
      <email>e.chevalier@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric BAUDIN, MD</last_name>
      <email>eric.baudin@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_fr.pdf</url>
    <description>RCP</description>
  </link>
  <link>
    <url>https://www.has-sante.fr/jcms/pprd_2983166/fr/lutathera-lutecium-177lu-oxodotreotide</url>
    <description>HAS</description>
  </link>
  <reference>
    <citation>Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after &quot;carcinoid&quot;: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. Review.</citation>
    <PMID>18565894</PMID>
  </reference>
  <reference>
    <citation>Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.</citation>
    <PMID>28076709</PMID>
  </reference>
  <reference>
    <citation>Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7.</citation>
    <PMID>29878866</PMID>
  </reference>
  <reference>
    <citation>Rudisile S, Gosewisch A, Wenter V, Unterrainer M, Böning G, Gildehaus FJ, Fendler WP, Auernhammer CJ, Spitzweg C, Bartenstein P, Todica A, Ilhan H. Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer. 2019 Aug 8;19(1):788. doi: 10.1186/s12885-019-6000-y.</citation>
    <PMID>31395036</PMID>
  </reference>
  <reference>
    <citation>Vaughan E, Machta J, Walker M, Toumpanakis C, Caplin M, Navalkissoor S. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Br J Radiol. 2018 Nov;91(1091):20180041. doi: 10.1259/bjr.20180041. Epub 2018 Mar 20.</citation>
    <PMID>29513039</PMID>
  </reference>
  <reference>
    <citation>Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, Ahmadzadehfar H. Safety of multiple repeated cycles of (177)Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214. doi: 10.1007/s00259-017-3652-1. Epub 2017 Mar 1.</citation>
    <PMID>28246882</PMID>
  </reference>
  <reference>
    <citation>Sabet A, Haslerud T, Pape UF, Sabet A, Ahmadzadehfar H, Grünwald F, Guhlke S, Biersack HJ, Ezziddin S. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):205-10. doi: 10.1007/s00259-013-2547-z. Epub 2013 Sep 13.</citation>
    <PMID>24030668</PMID>
  </reference>
  <reference>
    <citation>van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010 Mar;51(3):383-90. doi: 10.2967/jnumed.109.068957. Epub 2010 Feb 11.</citation>
    <PMID>20150247</PMID>
  </reference>
  <reference>
    <citation>Gleisner KS, Brolin G, Sundlöv A, Mjekiqi E, Östlund K, Tennvall J, Larsson E. Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging. J Nucl Med. 2015 Jul;56(7):976-84. doi: 10.2967/jnumed.115.155390. Epub 2015 May 21.</citation>
    <PMID>25999429</PMID>
  </reference>
  <reference>
    <citation>Sundlöv A, Sjögreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, Tennvall J. Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1480-1489. doi: 10.1007/s00259-017-3678-4. Epub 2017 Mar 22.</citation>
    <PMID>28331954</PMID>
  </reference>
  <reference>
    <citation>Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742. doi: 10.1007/s00259-018-4209-7. Epub 2018 Nov 30.</citation>
    <PMID>30506283</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lutetium Lu 177 dotatate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

